Recently, Rizzo S and colleagues reported EZH2 to be overexpressed in ovarian tumor-derived side population (SP) cells, which are stem cell-like cells enriched by chemotherapy, and demonstrated that EZH2 KD results in loss of SP cells and reduced anchorage-independent growth in ovarian tumor models [39]. The gene discussed is EZH2; the disease is ovarian neoplasm.